|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
European Association For The Study Of The
Liver; European Organisation For Research And Treatment Of Cancer.
EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Global Burden of Disease Liver Cancer
Collaboration. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu
MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, et al: The
burden of primary liver cancer and underlying etiologies from 1990
to 2015 at the global, regional, and national level: Results from
the global burden of disease study 2015. JAMA Oncol. 3:1683–1691.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2(16018)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang BH, Yang BH and Tang ZY: Randomized
controlled trial of screening for hepatocellular carcinoma. J
Cancer Res Clin Oncol. 130:417–422. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Grazi GL, Mazziotti A, Legnani C, Jovine
E, Miniero R, Gallucci A, Palareti G and Gozzetti G: The role of
tumor markers in the diagnosis of hepatocellular carcinoma, with
special reference to the des-gamma-carboxy prothrombin. Liver
Transpl Surg. 1:249–255. 1995.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ishii M, Gama H, Chida N, Ueno Y, Shinzawa
H, Takagi T, Toyota T, Takahashi T and Kasukawa R: Simultaneous
measurements of serum alpha-fetoprotein and protein induced by
vitamin K absence for detecting hepatocellular carcinoma. South
Tohoku District study group. Am J Gastroenterol. 95:1036–1040.
2000.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Marrero JA, Su GL, Wei W, Emick D,
Conjeevaram HS, Fontana RJ and Lok AS: Des-gamma carboxyprothrombin
can differentiate hepatocellular carcinoma from nonmalignant
chronic liver disease in american patients. Hepatology.
37:1114–1121. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Oda K, Ido A, Tamai T, Matsushita M,
Kumagai K, Mawatari S, Saishoji A, Kure T, Ohno K, Toyokura E, et
al: Highly sensitive Lens culinaris agglutinin-reactive
α-fetoprotein is useful for early detection of hepatocellular
carcinoma in patients with chronic liver disease. Oncol Rep.
26:1227–1233. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Oka H, Tamori A, Kuroki T, Kobayashi K and
Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic
patients monitored for development of hepatocellular carcinoma.
Hepatology. 19:61–66. 1994.PubMed/NCBI
|
|
11
|
Okuda H, Nakanishi T, Takatsu K, Saito A,
Hayashi N, Takasaki K, Takenami K, Yamamoto M and Nakano M: Serum
levels of des-gamma-carboxy prothrombin measured using the revised
enzyme immunoassay kit with increased sensitivity in relation to
clinicopathologic features of solitary hepatocellular carcinoma.
Cancer. 88:544–549. 2000.PubMed/NCBI
|
|
12
|
Wang CS, Lin CL, Lee HC, Chen KY, Chiang
MF, Chen HS, Lin TJ and Liao LY: Usefulness of serum
des-gamma-carboxy prothrombin in detection of hepatocellular
carcinoma. World J Gastroenterol. 11:6115–6119. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kagebayashi C, Yamaguchi I, Akinaga A,
Kitano H, Yokoyama K, Satomura M, Kurosawa T, Watanabe M, Kawabata
T, Chang W, et al: Automated immunoassay system for AFP-L3% using
on-chip electrokinetic reaction and separation by affinity
electrophoresis. Anal Biochem. 388:306–311. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Youden WJ: Index for rating diagnostic
tests. Cancer. 3:32–35. 1950.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kierans AS, Kang SK and Rosenkrantz AB:
The diagnostic performance of dynamic contrast-enhanced MR imaging
for detection of small hepatocellular carcinoma measuring Up to 2
cm: A meta-analysis. Radiology. 278:82–94. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Onishi H, Kim T, Imai Y, Hori M, Nagano H,
Nakaya Y, Tsuboyama T, Nakamoto A, Tatsumi M, Kumano S, et al:
Hypervascular hepatocellular carcinomas: Detection with gadoxetate
disodium-enhanced MR imaging and multiphasic multidetector CT. Eur
Radiol. 22:845–854. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sangiovanni A, Manini MA, Iavarone M,
Romeo R, Forzenigo LV, Fraquelli M, Massironi S, Della Corte C,
Ronchi G, Rumi MG, et al: The diagnostic and economic impact of
contrast imaging techniques in the diagnosis of small
hepatocellular carcinoma in cirrhosis. Gut. 59:638–644.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bergstrand CG and Czar B: Demonstration of
a new protein fraction in serum from the human fetus. Scand J Clin
Lab Invest. 8(174)1956.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Taketa K: Alpha-fetoprotein: Reevaluation
in hepatology. Hepatology. 12:1420–1432. 1990.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Aoyagi Y, Isemura M, Suzuki Y, Sekine C,
Soga K, Ozaki T and Ichida F: Fucosylated alpha-fetoprotein as
marker of early hepatocellular carcinoma. Lancet. 2:1353–1354.
1985.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Korekane H, Hasegawa T, Matsumoto A,
Kinoshita N, Miyoshi E and Taniguchi N: Development of an
antibody-lectin enzyme immunoassay for fucosylated
alpha-fetoprotein. Biochim Biophys Acta. 1820:1405–1411.
2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kumada T, Toyoda H, Tada T, Kiriyama S,
Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C and
Satomura S: High-sensitivity Lens culinaris
agglutinin-reactive alpha-fetoprotein assay predicts early
detection of hepatocellular carcinoma. J Gastroenterol. 49:555–563.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Oka H, Saito A, Ito K, Kumada T, Satomura
S, Kasugai H, Osaki Y, Seki T, Kudo M and Tanaka M: Collaborative
Hepato-Oncology Study Group of Japan. Multicenter prospective
analysis of newly diagnosed hepatocellular carcinoma with respect
to the percentage of Lens culinaris agglutinin-reactive
alpha-fetoprotein. J Gastroenterol Hepatol. 16:1378–1383.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Taketa K, Sekiya C, Namiki M, Akamatsu K,
Ohta Y, Endo Y and Kosaka K: Lectin-reactive profiles of
alpha-fetoprotein characterizing hepatocellular carcinoma and
related conditions. Gastroenterology. 99:508–518. 1990.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Nakamura K, Imajo N, Yamagata Y, Katoh H,
Fujio K, Tanaka T, Satomura S and Matsuura S: Liquid-phase binding
assay of alpha-fetoprotein using a sulfated antibody for bound/free
separation. Anal Chem. 70:954–957. 1998.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kawabata T, Wada HG, Watanabe M and
Satomura S: Electrokinetic analyte transport assay for
alpha-fetoprotein immunoassay integrates mixing, reaction and
separation on-chip. Electrophoresis. 29:1399–1406. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cucchetti A, Garuti F, Pinna AD and
Trevisani F: Italian Liver Cancer (ITA.LI.CA) group. Length time
bias in surveillance for hepatocellular carcinoma and how to avoid
it. Hepatol Res. 46:1275–1280. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hiramatsu N, Oze T and Takehara T:
Suppression of hepatocellular carcinoma development in hepatitis C
patients given interferon-based antiviral therapy. Hepatol Res.
45:152–161. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Oze T, Hiramatsu N, Yakushijin T, Miyazaki
M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, et al:
Post-treatment levels of α-fetoprotein predict incidence of
hepatocellular carcinoma after interferon therapy. Clin
Gastroenterol Hepatol. 12:1186–1195. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nagata H, Nakagawa M, Asahina Y, Sato A,
Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F,
et al: Effect of interferon-based and -free therapy on early
occurrence and recurrence of hepatocellular carcinoma in chronic
hepatitis C. J Hepatol. 67:933–939. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sasaki R, Yamasaki K, Abiru S, Komori A,
Nagaoka S, Saeki A, Hashimoto S, Bekki S, Kugiyama Y, Kuno A, et
al: Serum Wisteria floribunda agglutinin-positive Mac-2
binding protein values predict the development of hepatocellular
carcinoma among patients with chronic hepatitis C after sustained
virological response. PLoS One. 10(e0129053)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ioannou GN, Green PK and Berry K: HCV
eradication induced by direct-acting antiviral agents reduces the
risk of hepatocellular carcinoma. J Hepatol. 68:25–32.
2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kanwal F, Kramer J, Asch SM, Chayanupatkul
M, Cao Y and El-Serag HB: Risk of hepatocellular cancer in HCV
patients treated with direct-acting antiviral agents.
Gastroenterology. 153:996–1005.e1. 2017.PubMed/NCBI View Article : Google Scholar
|
